Cytosorbents Corporation (NASDAQ:CTSO) is set to announce second quarter earning results on Tuesday 4th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, CTSO to report 2Q20 loss of $ 0.08 per share.
For the full year, analysts anticipate top line of $ 36.78 million, while looking forward to loss of $ 0.35 per share bottom line.
Previous Quarter Performance
Cytosorbents Corporation unfold loss for the first quarter of $ 0.10 per share, from the revenue of $ 8.71 million. The quarterly revenues boosted 67.82 percent compared with the same quarter last year. According to street consensus, CTSO was expected to report 1Q20 loss of $ 0.13 per share from revenue of $ 7.00 million. The bottom line results beat street analysts by $ 0.03 or 23.08 percent, at the same time, top line results outshined analysts by $ 1.71 million or 24.43 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Cytosorbents Corporation
Stock Performance
According to the previous trading day, closing price of CTSO was $ 9.55, representing a 173.64 % increase from the 52 week low of $ 3.49 and a 18.65 % decrease over the 52 week high of $ 11.74.
The company has a market capital of $ 410.39 million and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CTSO” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Cytosorbents Corporation will be hosting a conference call at 4:45 PM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.cytosorbents.com
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The companys flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
